ArticleClinical case reports2020
Atopic dermatitis: Tofacitinib, an option for refractory disease.
Article in Clinical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- The JAK-STAT pathway in allergic diseases: from pathogenesis to targeted therapy.Biomarker research · 2026Review
- Treatment of Atopic Dermatitis in Children.Cureus · 2024Review
- The Molecular Signature Related to Local Inflammatory and Immune Response in Canine Cutaneous Hypersensitivity Reactions: A Preliminary Study.Current issues in molecular biology · 2024Article
- Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.Frontiers in immunology · 2024Review
- Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches.Frontiers in immunology · 2024Review
- Two cases of bullous pemphigoid effectively treated with oral tofacitinib.JAAD case reports · 2023Article
- JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.Frontiers in immunology · 2022Review
- JAK inhibitors in the treatment of atopic dermatitis.The Journal of allergy and clinical immunology · 2021Review
- Atopic dermatitis: Tofacitinib, an option for refractory disease.Clinical case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate-severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.